Voyager Therapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD -111.97 M

Voyager Therapeutics, Inc. Operating Cash Flow is USD -111.97 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -953.38% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Voyager Therapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 13.12 M, a -82.88% change year over year.
  • Voyager Therapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 76.63 M, a 3,391.12% change year over year.
  • Voyager Therapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 2.19 M, a -102.46% change year over year.
  • Voyager Therapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -89.21 M, a -15.27% change year over year.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities